Store-operated calcium entry suppressed the TGF-β1/Smad3 signaling pathway in glomerular mesangial cells

Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F729-F739. doi: 10.1152/ajprenal.00483.2016. Epub 2017 Jun 21.

Abstract

Our previous study demonstrated that the abundance of extracellular matrix proteins was suppressed by store-operated Ca2+ entry (SOCE) in mesangial cells (MCs). The present study was conducted to investigate the underlying mechanism focused on the transforming growth factor-β1 (TGF-β1)/Smad3 pathway, a critical pathway for ECM expansion in diabetic kidneys. We hypothesized that SOCE suppressed ECM protein expression by inhibiting this pathway in MCs. In cultured human MCs, we observed that TGF-β1 (5 ng/ml for 15 h) significantly increased Smad3 phosphorylation, as evaluated by immunoblot. However, this response was markedly inhibited by thapsigargin (1 µM), a classical activator of store-operated Ca2+ channels. Consistently, both immunocytochemistry and immunoblot showed that TGF-β1 significantly increased nuclear translocation of Smad3, which was prevented by pretreatment with thapsigargin. Importantly, the thapsigargin effect was reversed by lanthanum (La3+; 5 µM) and GSK-7975A (10 µM), both of which are selective blockers of store-operated Ca2+ channels. Furthermore, knockdown of Orai1, the pore-forming subunit of the store-operated Ca2+ channels, significantly augmented TGF-β1-induced Smad3 phosphorylation. Overexpression of Orai1 augmented the inhibitory effect of thapsigargin on TGF-β1-induced phosphorylation of Smad3. In agreement with the data from cultured MCs, in vivo knockdown of Orai1 specific to MCs using a targeted nanoparticle small interfering RNA delivery system resulted in a marked increase in abundance of phosphorylated Smad3 and in nuclear translocation of Smad3 in the glomerulus of mice. Taken together, our results indicate that SOCE in MCs negatively regulates the TGF-β1/Smad3 signaling pathway.

Keywords: Orai1; Smad3; mesangial cells; store-operated Ca2+ entry; transforming growth factor-β1.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Active Transport, Cell Nucleus
  • Animals
  • Calcium Channel Blockers / pharmacology
  • Calcium Signaling*
  • Cells, Cultured
  • Collagen Type IV / metabolism
  • Enzyme Inhibitors / pharmacology
  • Fibronectins / metabolism
  • Humans
  • Male
  • Mesangial Cells / drug effects*
  • Mesangial Cells / metabolism
  • Mice, Inbred C57BL
  • ORAI1 Protein / antagonists & inhibitors
  • ORAI1 Protein / genetics
  • ORAI1 Protein / metabolism*
  • Phosphorylation
  • RNA Interference
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / antagonists & inhibitors
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism
  • Smad3 Protein / metabolism*
  • Time Factors
  • Transfection
  • Transforming Growth Factor beta1 / pharmacology*

Substances

  • Calcium Channel Blockers
  • Collagen Type IV
  • Enzyme Inhibitors
  • Fibronectins
  • ORAI1 Protein
  • ORAI1 protein, human
  • Orai1 protein, mouse
  • SMAD3 protein, human
  • Smad3 Protein
  • Smad3 protein, mouse
  • TGFB1 protein, human
  • Transforming Growth Factor beta1
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases